A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with nonsevere Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW trial)

BMJ Open

Volumn 4, Issue 8, 2014, Pages

  Grigg, M J ^a   William, T ^a,b   Dhanaraj, P ^b   Menon, J ^b   Barber, B E ^a   Von Seidlein, L ^a,c   Rajahram, G ^a,b   Price, R N ^a,d   Anstey, N M ^a,e   Yeo, T W ^a,f  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b Infectious Diseases Unit Clinical Research Centre Queen Elizabeth Hospital   (Malaysia)

^c MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e ROYAL DARWIN HOSPITAL   (Australia)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; MEFLOQUINE;

ANALYSIS; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GAMETOCYTE; HEALTH CARE COST; HUMAN; HUMAN TISSUE; LENGTH OF STAY; MALAYSIA; MALE; PARASITE CLEARANCE; PLASMODIUM KNOWLESI MALARIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; COMPARATIVE STUDY; MALARIA; METHODOLOGY; PARASITOLOGY; PLASMODIUM KNOWLESI; SEVERITY OF ILLNESS INDEX;

ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; FEMALE; HUMANS; MALARIA; MALAYSIA; MALE; MEFLOQUINE; PLASMODIUM KNOWLESI; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 84924278427     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006005     Document Type: Article

References (60)

1. Cox-Singh J, Davis TM, Lee KS, et al. Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 2008;46:165-71. (Pubitemid 351269152)
2. Jongwutiwes S, Putaporntip C, Iwasaki T, et al. Naturally acquired Plasmodium knowlesi malaria in human, Thailand. Emerg Infect Dis 2004;10:2211-13. (Pubitemid 39587350)
3. Marchand RP, Culleton R, Maeno Y, et al. Co-infections of Plasmodium knowlesi, P. falciparum, and P. vivax among humans and anopheles dirus mosquitoes, Southern Vietnam. Emerg Infect Dis 2011;17:1232-9.
4. Ng OT, Ooi EE, Lee CC, et al. Naturally acquired human Plasmodium knowlesi infection, Singapore. Emerg Infect Dis 2008;14:814-16. (Pubitemid 351838651)
5. Luchavez J, Espino F, Curameng P, et al. Human infections with Plasmodium knowlesi, the Philippines. Emerg Infect Dis 2008;14:811-13. (Pubitemid 351838650)
6. Cox-Singh J, Singh B. Knowlesi malaria: newly emergent and of public health importance? Trends Parasitol 2008;24:406-10.
7. Ninan T, Nalees K, Newin M, et al. Plasmodium knowlesi malaria infection in human. Brunei Int Med J 2012;8:358-61.
8. Jiang N, Chang Q, Sun X, et al. Co-infections with Plasmodium knowlesi and other malaria parasites, Myanmar. Emerg Infect Dis 2010;16:1476-8.
9. Khim N, Siv S, Kim S, et al. Plasmodium knowlesi infection in humans, Cambodia, 2007-2010. Emerg Infect Dis 2011;17:1900-2.
10. Tyagi RK, Das MK, Singh SS, et al. Discordance in drug resistance-associated mutation patterns in marker genes of Plasmodium falciparum and Plasmodium knowlesi during coinfections. J Antimicrob Chemother 2013;68:1081-8.
11. Zhu HM, Li J, Zheng H. [Human natural infection of Plasmodium knowlesi]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2006;24:70-1.
12. Vythilingam I. Plasmodium knowlesi in humans: a review on the role of its vectors in Malaysia. Trop Biomed 2010;27:1-12.
13. Baird JK. Malaria zoonoses. Travel Med Infect Dis 2009;7:269-77.
14. Singh B, Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin Microbiol Rev 2013;26:165-84.
15. Barber BE, William T, Grigg MJ, et al. Limitations of microscopy to differentiate Plasmodium species in a region co-endemic for Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi. Malar J 2013;12:8.
16. Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004;363:1017-24. (Pubitemid 38410774)
17. Anderios FEA. Detection of malaria parasites in Sabah by nested PCR: a focus of naturally acquired P knowlesi infections. Sains Malaysiana 2008;32:137-41.
18. Naing DKS, Anderios F, Lin Z. Geographic and ethnic distribution of P knowlesi infection in Sabah, Malaysia. Int J Collaborative Res Int Med Public Health 2011;3:391-400.
19. Singh B, Daneshvar C. Plasmodium knowlesi malaria in Malaysia. Med J Malaysia 2010;65:166-72.
20. Joveen-Neoh WF, Chong KL, Wong CM, et al. Incidence of malaria in the interior division of Sabah, Malaysian Borneo, based on nested PCR. J Parasitol Res 2011;2011:104284.
21. Barber BE, William T, Grigg MJ, et al. A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from plasmodium knowlesi and plasmodium vivax but no mortality with early referral and artesunate therapy. Clin Infect Dis 2013;56:383-97.
22. Ministry of Health Malaysia, V. B. D. C. P. Vector control in Malaysia. Consultative meeting/workshop on management of vector control programs, 11-15 August 2008; Siem Reap, Cambodia. vc-policy/vc-malaysia.pdf. http://www.actmalaria.net/files/vector-control/ (accessed 15 Jul 2012).
23. APMEN V: Vivax Working Group Meeting. 2013. http://apmen.org/storage/ apmen-v/apmen-v-powerpoint-presentations-all/day-1/APMENV-S6-Artesunate- mefloquine%20vs.%20chloroquine%20in%20patients%20with%20P.vivax%20- %20a%20randomized%20open%20label%20trial%20Sabah-Tim%20William1.pdf (accessed 4 Jan 2014).
24. Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and laboratory features of human Plasmodium knowlesi infection. Clin Infect Dis 2009;49:852-60.
25. William T, Menon J, Rajahram G, et al. Severe Plasmodium knowlesi malaria in a tertiary care hospital, Sabah, Malaysia. Emerg Infect Dis 2011;17:1248-55.
26. Rajahram GS, Barber BE, William T, et al. Deaths due to Plasmodium knowlesi malaria in Sabah, Malaysia: association with reporting as Plasmodium malariae and delayed parenteral artesunate. Malar J 2012;11:284.
27. Daneshvar C, Davis TM, Cox-Singh J, et al. Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections. Malar J 2010;9:238.
28. Barber BE, William T, Jikal M, et al. Plasmodium knowlesi malaria in children. Emerg Infect Dis 2011;17:814-20.
29. Bronner U, Divis PC, Farnert A, et al. Swedish traveller with Plasmodium knowlesi malaria after visiting Malaysian Borneo. Malar J 2009;8:15.
30. Figtree M, Lee R, Bain L, et al. Plasmodium knowlesi in human, Indonesian Borneo. Emerg Infect Dis 2010;16:672-4.
31. Hoosen A, Shaw MTM. Plasmodium knowlesi in a traveller returning to New Zealand. Travel Med Infect Dis 2011;9:144-8.
32. Berry A, Iriart X, Wilhelm N, et al. Imported Plasmodium knowlesi malaria in a French tourist returning from Thailand. Am J Trop Med Hyg 2011;84:535-8.
33. Ta Tang T-H, Ali-Tammam M, Martínez Mdel C, et al. First case of detection of Plasmodium knowlesi in Spain by real time PCR in a traveller from Southeast Asia. Malar J 2010;9:219.
34. Lee CE, Adeeba K, Freigang G. Human Plasmodium knowlesi infections in Klang Valley, Peninsula Malaysia: a case series. Med J Malaysia 2010;65:63-5.
35. Kuo M-C, Chiang T-Y, Chan C-W, et al. A case report of Simian Malaria, Plasmodium knowlesi, in a Taiwanese Traveler from Palawan Island, the Philippines. Epidemiol Bull 2009;25:178-91.
36. WHO. WHO malaria treatment guidelines. Geneva. 2010.
37. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994;88(Suppl 1):S41-3. (Pubitemid 24206486)
38. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 1999;354:739-49. (Pubitemid 29365622)
39. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007;77:181-92.
40. Ambler MT, Dubowitz LM, Arunjerdja R, et al. The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria. Malar J 2009;8:207.
41. Krudsood S, Looareesuwan S, Silachamroon U, et al. Artesunate and mefloquine given simultaneously for three days via a prepacked blister is equally effective and tolerated as a standard sequential treatment of uncomplicated acute Plasmodium falciparum malaria: randomized, double-blind study in Thailand. Am J Trop Med Hyg 2002;67:465-72. (Pubitemid 35403159)
42. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009;(3):CD007483.
43. Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999;28:808-15. (Pubitemid 29169420)
44. Fatih FA, Staines HM, Siner A, et al. Susceptibility of human Plasmodium knowlesi infections to anti-malarials. Malar J 2013;12:425.
45. Lau YL, Tan LH, Chin LC, et al. Plasmodium knowlesi reinfection in human. Emerg Infect Dis 2011;17:1314-15.
46. WHO. WHO management of severe malaria Geneva. 2013:1-89.
47. Ministry of Health Malaysia, V. B. D. C. P. Management guidelines of malaria in Malaysia. Malaysia: Ministry of Health, 2013. http://www.moh.gov.my/ index.php
48. Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 2010;10:405-16.
49. WHO. Methods for surveillance of antimalarial drug efficacy. WHO, 2009.
50. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996;347:1654-8. (Pubitemid 26177386)
51. Angus BJ, Thaiaporn I, Chanthapadith K, et al. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002;46:778-82. (Pubitemid 34157663)
52. Price R, Simpson JA, Teja-Isavatharm P, et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob Agents Chemother 1999;43:341-6. (Pubitemid 29079169)
53. Padley D, Moody AH, Chiodini PL, et al. Use of a rapid, single-round, multiplex PCR to detect malarial parasites and identify the species present. Ann Trop Med Parasitol 2003;97:131-7. (Pubitemid 36543234)
54. Imwong M, Tanomsing N, Pukrittayakamee S, et al. Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol 2009;47:4173-5.
55. Divis PC, Shokoples SE, Singh B, et al. A TaqMan real-time PCR assay for the detection and quantitation of Plasmodium knowlesi. Malar J 2010;9:344.
56. McCutchan TF, Piper RC, Makler MT. Use of malaria rapid diagnostic test to identify Plasmodium knowlesi infection. Emerg Infect Dis 2008;14:1750-2.
57. Barber BE, William T, Grigg MJ, et al. Evaluation of the sensitivity of a pldh-based and an aldolase-based rapid diagnostic test for diagnosis of uncomplicated and severe malaria caused by PCR-confirmed plasmodium knowlesi, Plasmodium falciparum, and plasmodium vivax. J Clin Microbiol 2013;51:1118-23.
58. Grigg MJ, William T, Barber BE, et al. Combining parasite lactate dehydrogenase-based and histidine rich protein-2 rapid tests to improve specificity for the diagnosis of malaria due to Plasmodium knowlesi and other Plasmodium species in Sabah, Malaysia. J Clin Microbiol 2014;52:2053-60.
59. Good Clinical Practice: ICH guidelines. http://www.ich.org/products/ guidelines/efficacy/efficacy-single/article/good-clinical-practice.html
60. World Wide Anti-malarial Resistance Network (WWARN). http://www.wwarn.org (accessed 21 Jul 2012).